Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - Link Fund Solutions Ltd:HVIVO PLC
Form 8.3 - Link Fund Solutions Ltd:HVIVO PLC
Form 8.3 - Link Fund Solutions Ltd:HVIVO PLC
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
DGAP-News: Ergomed plc: Lewis Cameron, ehemals Leiter der globalen klinischen Entwicklung bei Covance, zum Chief Operating Officer ernannt
DGAP-News: Ergomed plc: Lewis Cameron, ehemals Leiter der globalen klinischen Entwicklung bei Covance, zum Chief Operating Officer ernannt
DGAP-News: Ergomed plc: Lewis Cameron, ehemals Leiter der globalen klinischen Entwicklung bei Covance, zum Chief Operating Officer ernannt
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - Consort Medical Plc
Form 8.3 - Consort Medical Plc
Form 8.3 - Consort Medical Plc
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
The Best Dividend Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/778459/getty-dividend-stocks-growing-money-income-cash.jpg
The Best Dividend Stocks to Buy Right Now

Dividend stocks can be boring, especially when AI-fueled stock gains are proliferating. Still, for long-term investors, buying sustainable dividend stocks with solid growth potential is a timeless

Want $200 in Monthly Dividends? Invest $36,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/777833/a-person-counting-money-in-their-living-room.jpg
Want $200 in Monthly Dividends? Invest $36,000 in These 3 Stocks

Dividend stocks normally pay you every quarter, which isn't optimal if you want to generate consistent monthly income from your investments. But you can get around that by investing in stocks that

Will AT&T Increase Its Dividend This Year?: https://g.foolcdn.com/editorial/images/776996/a-couple-reviewing-a-statement.jpg
Will AT&T Increase Its Dividend This Year?

Before the pandemic disrupted its operations, AT&T (NYSE: T) was a reliable dividend stock. Not only that, but it was also a dividend-growth stock. For decades, the company increased dividend

Why AST SpaceMobile Stock Is Up Again Today: https://g.foolcdn.com/editorial/images/777718/earth-planet-and-satellite-view-from-space-getty.jpg
Why AST SpaceMobile Stock Is Up Again Today

A day after AST SpaceMobile (NASDAQ: ASTS) stock got a big boost from the company solidifying a key partnership, Wall Street is rallying to the cause. Shares of the space communications company got

Why AST SpaceMobile Stock Is Blasting Off Today: https://g.foolcdn.com/editorial/images/777571/artificial-satellites-orbiting-the-planet-earth-space-force-military-satellites-getty.jpg
Why AST SpaceMobile Stock Is Blasting Off Today

Space mobility specialist AST SpaceMobile (NASDAQ: ASTS) is formalizing ties with partner AT&T ahead of its commercial launch this summer. That news, along with AST's latest earnings report, has the

Better Telecom Stock: AT&T vs. T-Mobile: https://g.foolcdn.com/editorial/images/777021/using-smartphone-while-outside.jpg
Better Telecom Stock: AT&T vs. T-Mobile

AT&T (NYSE: T) and T-Mobile US (NASDAQ: TMUS) are two of the three major telcos that dominate the U.S. wireless market, but each arrived at that point from different places.

AT&T is a former Baby

3 High-Yield Dividend Stocks to Buy Hand Over Fist in May: https://g.foolcdn.com/editorial/images/776810/high-yield-low-risk.jpg
3 High-Yield Dividend Stocks to Buy Hand Over Fist in May

Investors have enjoyed higher Treasury yields, serving up passive income over the past couple of years. However, there's still an abundance of quality dividend stocks that offer potential price

Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead: https://g.foolcdn.com/editorial/images/775882/a-doctor-looking-at-a-tablet-with-another-person.jpg
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead

Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.

The company continually runs into

Could AT&T Stock Help You Retire a Millionaire?: https://g.foolcdn.com/editorial/images/775806/building-with-_att-logo-on-front_att.jpg
Could AT&T Stock Help You Retire a Millionaire?

Retiring wealthy isn't necessarily about hitting the home run investment. Instead, it can be about consistently hitting singles and doubles over time.

U.S. telecom company AT&T (NYSE: T) probably

Want an Extra $500 in Annual Dividend Income? Invest $5,890 in These 3 High-Yield Dividend Stocks.: https://g.foolcdn.com/editorial/images/775860/investing-screen-analysis-investor-growth-stocks-getty.jpg
Want an Extra $500 in Annual Dividend Income? Invest $5,890 in These 3 High-Yield Dividend Stocks.

Investors eager to bulk up their passive income streams can do so without breaking the bank.

At recent prices, Hercules Capital (NYSE: HTGC), Altria Group (NYSE: MO), and AT&T (NYSE: T) offer an